Literature DB >> 23640055

Nuclear monomeric integrin αv in cancer cells is a coactivator regulated by thyroid hormone.

Hung-Yun Lin1, Yee-Fun Su, Meng-Ti Hsieh, Sharon Lin, Ran Meng, David London, Cassie Lin, Heng-Yuan Tang, Jaulang Hwang, Faith B Davis, Shaker A Mousa, Paul J Davis.   

Abstract

Thyroid hormone induces tumor cell and blood vessel cell proliferation via a cell surface receptor on heterodimeric integrin αvβ3. We investigated the role of thyroid hormone-induced internalization of nuclear integrin αv monomer. Physiological concentration of thyroxine (free T4, 10(-10) M), but not 3,5,3'-triiodo-l-thyronine (T3), induced cellular internalization and nuclear translocation of integrin αv monomer in human non-small-cell lung cancer (H522) and ovarian carcinoma (OVCAR-3) cells. T4 did not complex with integrin αv monomer during its internalization. The αv monomer was phosphorylated by activated ERK1/2 when it heterodimerized with integrin β3 in vitro. Nuclear αv complexed with transcriptional coactivator proteins, p300 and STAT1, and with corepressor proteins, NCoR and SMRT. Nuclear αv monomer in T4-exposed cells, but not integrin β3, bound to promoters of specific genes that have important roles in cancer cells, including estrogen receptor-α, cyclooxygenase-2, hypoxia-inducible factor-1α, and thyroid hormone receptor β1 in chromatin immunoprecipitation assay. In summary, monomeric αv is a novel coactivator regulated from the cell surface by thyroid hormone for the expression of genes involved in tumorigenesis and angiogenesis. This study also offers a mechanism for modulation of gene expression by thyroid hormone that is adjunctive to the nuclear hormone receptor (TR)-T3 pathway.

Entities:  

Keywords:  angiogenesis; carcinogenesis; gene expression; thyroxine

Mesh:

Substances:

Year:  2013        PMID: 23640055     DOI: 10.1096/fj.12-227132

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  26 in total

Review 1.  Nongenomic actions of thyroid hormone.

Authors:  Paul J Davis; Fernando Goglia; Jack L Leonard
Journal:  Nat Rev Endocrinol       Date:  2015-12-15       Impact factor: 43.330

Review 2.  Thyroid hormone and anti-apoptosis in tumor cells.

Authors:  Hung-Yun Lin; Gennadi V Glinsky; Shaker A Mousa; Paul J Davis
Journal:  Oncotarget       Date:  2015-06-20

3.  The thyroid hormone-αvβ3 integrin axis in ovarian cancer: regulation of gene transcription and MAPK-dependent proliferation.

Authors:  E Shinderman-Maman; K Cohen; C Weingarten; D Nabriski; O Twito; L Baraf; A Hercbergs; P J Davis; H Werner; M Ellis; O Ashur-Fabian
Journal:  Oncogene       Date:  2015-07-13       Impact factor: 9.867

4.  Excess Maternal Thyroxine Alters the Proliferative Activity and Angiogenic Profile of Growth Cartilage of Rats at Birth and Weaning.

Authors:  Lorena Gabriela Rocha Ribeiro; Juneo Freitas Silva; Natália de Melo Ocarino; Cíntia Almeida de Souza; Eliane Gonçalves de Melo; Rogéria Serakides
Journal:  Cartilage       Date:  2016-12-28       Impact factor: 4.634

Review 5.  Small molecule hormone or hormone-like ligands of integrin αVβ3: implications for cancer cell behavior.

Authors:  Paul J Davis; Shaker A Mousa; Vivian Cody; Heng-Yuan Tang; Hung-Yun Lin
Journal:  Horm Cancer       Date:  2013-08-14       Impact factor: 3.869

Review 6.  Nanotetrac targets integrin αvβ3 on tumor cells to disorder cell defense pathways and block angiogenesis.

Authors:  Paul J Davis; Hung-Yun Lin; Thangirala Sudha; Murat Yalcin; Heng-Yuan Tang; Aleck Hercbergs; John T Leith; Mary K Luidens; Osnat Ashur-Fabian; Sandra Incerpi; Shaker A Mousa
Journal:  Onco Targets Ther       Date:  2014-09-18       Impact factor: 4.147

Review 7.  Recurrence of differentiated thyroid carcinoma during full TSH suppression: is the tumor now thyroid hormone dependent?

Authors:  Paul J Davis; Aleck Hercbergs; Mary K Luidens; Hung-Yun Lin
Journal:  Horm Cancer       Date:  2014-10-08       Impact factor: 3.869

Review 8.  Cancer Cell Gene Expression Modulated from Plasma Membrane Integrin αvβ3 by Thyroid Hormone and Nanoparticulate Tetrac.

Authors:  Paul J Davis; Gennadi V Glinsky; Hung-Yun Lin; John T Leith; Aleck Hercbergs; Heng-Yuan Tang; Osnat Ashur-Fabian; Sandra Incerpi; Shaker A Mousa
Journal:  Front Endocrinol (Lausanne)       Date:  2015-01-12       Impact factor: 5.555

Review 9.  Actions of Thyroid Hormone Analogues on Chemokines.

Authors:  Paul J Davis; Gennadi V Glinsky; Hung-Yun Lin; Shaker A Mousa
Journal:  J Immunol Res       Date:  2016-07-17       Impact factor: 4.818

Review 10.  Actions of Thyroid Hormones on Thyroid Cancers.

Authors:  Shaker A Mousa; Aleck Hercbergs; Hung-Yun Lin; Kelly A Keating; Paul J Davis
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-21       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.